Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361328 · ClinicalTrials.gov registry record · NA
Personalized Ultrasonic Brain Stimulation for Fibromyalgia
A NA study of Fibromyalgia (FM), sponsored by University of Utah.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07361328: Recruiting NA study of Fibromyalgia (FM), sponsored by University of Utah.
NCT07361328 is a NA study of Fibromyalgia (FM) that is actively recruiting participants, run by University of Utah. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07361328, a NA study of Fibromyalgia (FM), is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this research is to evaluate a new kind of noninvasive brain stimulation intervention using the investigational ultrasound device, which might be useful for treating fibromyalgia. The device is for investigational use only and is not yet approved by the FDA for the intended use. * Participants will be asked to visit the study center 7 times for in-person assessment and treatment sessions. In addition, participants will be asked to complete an online assessment 7 times. During in-person or online visits: * Participants will undergo an MRI scan twice during the first and last in-person visit (1 hour each) The second MRI may be optional. * There will be 6 treatment sessions (45 minutes each) within a 2-week period * The online assessment occurs (15 minutes each) * two consecutive days before the first treatment session * 15 days after the first treatment session * 22 days after the first treatment session * 29 days after the first treatment session * 44 days after the first treatment session * 60 days after the first treatment session
Primary Outcome
Pain score on the 0-10 scale at Day 15 following the first treatment
Conditions Studied
Interventions
- DEVICE Sham (No Treatment)
- DEVICE Low-intensity ultrasound brain stimulation
Study Locations (1)
Utah
- Pain Research Center, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT07361328 shows while recruiting
NCT07361328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Fibromyalgia (FM) appearing as the primary indexed condition, and to 2 interventions - of which Sham (No Treatment) is the first listed.
NCT07361328 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT07361328 about?
NCT07361328 is a clinical study titled "Personalized Ultrasonic Brain Stimulation for Fibromyalgia". The primary purpose of this research is to evaluate a new kind of noninvasive brain stimulation intervention using the investigational ultrasound device, which might be useful for treating fibromyalgia. The device is for investigational use only and is not yet approved by the FDA for the intended us...
What is the current status of trial NCT07361328?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-01-05. Estimated completion is 2028-12-31.
What conditions does trial NCT07361328 study?
This clinical trial studies the following conditions: Fibromyalgia (FM).
What interventions are being tested in trial NCT07361328?
The interventions under investigation include: Sham (No Treatment) (DEVICE), Low-intensity ultrasound brain stimulation (DEVICE).
Who is sponsoring clinical trial NCT07361328?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07361328 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia (FM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07361328's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI